【摘要】：目的：本課題通過對(duì)中藥抗病毒制劑對(duì)比匹多莫德口服液(商品名：芙露飲)治療濕熱下注型年輕女性宮頸高危型人乳頭瘤病毒(high-risk Human Papilloma Virus, hrHPV)感染的臨床研究,以此來評(píng)價(jià)中藥抗病毒制劑臨床治療的有效性以及安全性。方法：選擇符合納入標(biāo)準(zhǔn)的于2015年6月-2015年12月在常州市中醫(yī)醫(yī)院婦科門診就診及住院的年齡為25-35歲之間的濕熱下注型hrHPV感染患者共60例,將病人隨機(jī)分為2組,對(duì)照組(芙露飲組),治療組(中藥抗病毒制劑組),每組30例,按研究方案進(jìn)行治療,通過治療前后及兩組組間對(duì)比來評(píng)價(jià)中藥抗病毒制劑的臨床療效,并通過觀察治療組的臨床生化指標(biāo)來評(píng)價(jià)中藥抗病毒制劑的安全性。結(jié)果：1.中醫(yī)臨床癥候積分的比較：(1)兩組治療前后各項(xiàng)中醫(yī)癥狀積分的比較：治療組在治療后對(duì)濕熱下注型年輕女性富頸hrHPV感染患者的各項(xiàng)臨床癥狀均有明顯改善。對(duì)照組在治療后對(duì)帶下情況及全身癥狀較前無或僅有輕微改善。(2)中醫(yī)臨床癥候總積分的比較：治療組的中醫(yī)臨床癥候總積分在治療前后的比較有顯著的統(tǒng)計(jì)學(xué)意義(p=0.00,p0.01),對(duì)照組在治療前后的臨床癥候積分方面意義不顯著,且兩組之間對(duì)比,差異具有統(tǒng)計(jì)學(xué)意義(p0.05)。2.hrHPV病毒載量及轉(zhuǎn)陰率的比較：(1)治療組與對(duì)照組在治療前后的病毒載量比較均具有顯著統(tǒng)計(jì)學(xué)意義,兩組病毒載量治療前后差值比較有統(tǒng)計(jì)學(xué)意義(p=0.01,p0.05),且治療組降低hrHPV病毒載量明顯優(yōu)于對(duì)照組,兩組對(duì)比具有明顯差異(p0.05)。(2)對(duì)照組在治療3個(gè)月、6個(gè)月后轉(zhuǎn)陰率為20%、33.3%,治療組在治療3個(gè)月、6個(gè)月后的轉(zhuǎn)陰率為36.7%、63.3%。兩組在治療3個(gè)月、6個(gè)月后的轉(zhuǎn)陰率的比較均具有統(tǒng)計(jì)學(xué)意義(p0.05)。3.治療前后總有效率的比較：對(duì)照組痊愈率為10%,總有效率63.3%,治療組痊愈率為26.7%,總有效率為86.7%。兩組總有效率的比較有顯著統(tǒng)計(jì)學(xué)意義(p=0.00,p0.01)。4.安全性觀察：治療組在治療3個(gè)月、6個(gè)月后查肝腎功能、血尿常規(guī)、凝血功能、血生化等指標(biāo)未見明顯異常,兩組治療期間未出現(xiàn)與服用藥物明顯相關(guān)的不良反應(yīng)。結(jié)論：中藥抗病毒制劑及芙露飲均能夠明顯縮短年輕女性宮頸hrHPV感染的臨床自愈時(shí)限,能夠清除hrHPV病毒,降低病毒載量,改善患者的臨床癥狀。中西藥及早干預(yù)治療有顯著的臨床治療意義,且中藥治療效果明顯優(yōu)于西藥治療。中藥經(jīng)濟(jì)實(shí)惠,安全無毒副作用。
[Abstract]:Objective: to study the clinical study on the treatment of high risk human papillomavirus (high-risk Human Papilloma Virus, hrHPV) infection of cervix of young women with dampness and heat by contrasting pidomod oral liquid (commercial name: Fructus decoction) with antiviral preparation of traditional Chinese medicine. To evaluate the efficacy and safety of traditional Chinese medicine antiviral preparations. Methods: a total of 60 patients with hrHPV infection, aged 25-35 years, who were admitted to the department of gynecology of Changzhou traditional Chinese Medicine Hospital from June 2015 to December 2015, were randomly divided into two groups. The control group (Flo Yin group) and the treatment group (traditional Chinese medicine antiviral preparation group), 30 cases in each group, were treated according to the research plan. The clinical efficacy of traditional Chinese medicine antiviral preparation was evaluated by comparison before and after treatment and between the two groups. The safety of traditional Chinese medicine antiviral preparations was evaluated by observing the clinical biochemical indexes of the treatment group. Results: 1. Comparison of TCM clinical symptom scores: (1) comparison of TCM symptom scores before and after treatment: after treatment, the clinical symptoms of young female patients with hrHPV infection with rich neck were obviously improved in the treatment group. In the control group, there was no or only slight improvement in the subband condition and systemic symptoms after treatment. (2) comparison of the total score of TCM clinical symptoms: the total score of TCM clinical symptoms in the treatment group was significantly different before and after treatment. Statistical significance (p0. 00. P0.01), the control group had no significant significance in the clinical symptom score before and after treatment, and the comparison between the two groups, The difference was statistically significant (p0. 05). The comparison of viral load and negative rate of 2.hrHPV: (1) the viral load of treatment group and control group were significantly different before and after treatment. The difference of viral load between the two groups before and after treatment was statistically significant (p0. 01% p0. 05), and the decrease of hrHPV viral load in the treatment group was significantly better than that in the control group. There was significant difference between the two groups (p0. 05). (2). In the control group, the rate of turning negative after 3 months and 6 months was 20 and 33. 3 respectively. In the treatment group, the rate of turning negative after 3 months and 6 months was 36. 7% and 63. 3% respectively. After 3 months and 6 months of treatment, there were significant differences in the rate of negative conversion between the two groups (p 0.05). Comparison of the total effective rate before and after treatment: the cure rate of the control group was 10, the total effective rate was 63.3, the cure rate of the treatment group was 26.7and the total effective rate was 86.7. The total effective rate of the two groups was significantly higher than that of the control group (p0. 00p 0. 01). 4. Safety observation: the liver and kidney function, blood and urine routine, coagulation function and blood biochemistry were not abnormal in the treatment group after 3 months and 6 months, and there were no obvious adverse reactions associated with taking drugs during the treatment period. Conclusion: both antiviral preparations and Fructus decoction can significantly shorten the time limit of self-healing of cervical hrHPV infection in young women, eliminate hrHPV virus, reduce viral load and improve the clinical symptoms of the patients. Early intervention of Chinese and western medicine has significant clinical significance, and the effect of traditional Chinese medicine is obviously better than that of western medicine. Traditional Chinese medicine is economical and safe without toxic side effects.
【學(xué)位授予單位】：南京中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R271.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 趙進(jìn)生;吳鴻銀;;抗病毒制劑——干擾素(Интереферон)[J];南藥譯叢;1961年01期

2 張雅德;;治療流感的新抗病毒制劑是否能滿足臨床需要[J];國外醫(yī)學(xué)情報(bào);1998年03期

3 孫敬方;劉興福;;新型禽用抗病毒制劑的研制與應(yīng)用[J];實(shí)驗(yàn)動(dòng)物與比較醫(yī)學(xué);2006年03期

4 史久華;;即將問世的基因工程制品[J];國外醫(yī)學(xué).生物制品分冊(cè);1983年03期

5 黃大有;病毒生物學(xué)及抗病毒制劑的某些新進(jìn)展[J];北京醫(yī)學(xué)院學(xué)報(bào);1983年01期

6 孫永濤,白雪帆,SylviaLee-huang;新一代抗病毒制劑——MAP30[J];肝臟;2001年S1期

7 陳春榮;防止危險(xiǎn)藥品對(duì)護(hù)士造成危害[J];國外醫(yī)學(xué).護(hù)理學(xué)分冊(cè);2002年09期

8 王勇翔;;干擾正常衣殼蛋白組裝的小分子物質(zhì)可發(fā)展成抗病毒制劑[J];國外醫(yī)學(xué)(微生物學(xué)分冊(cè));2003年02期

9 王臨旭;孫永濤;楊為松;;新一代抗HIV植物蛋白-MAP30[J];傳染病信息;2002年01期

10 褚盤棣;;日本新開發(fā)的生物制品和抗病毒制劑[J];藥學(xué)進(jìn)展;1990年01期

相關(guān)會(huì)議論文 前4條

1 張代寶;吳志明;趙明軍;王淑娟;謝彩華;張林海;閆若潛;;雞基因工程復(fù)合抗病毒制劑凍干保護(hù)劑的篩選[A];中國畜牧獸醫(yī)學(xué)會(huì)動(dòng)物傳染病學(xué)分會(huì)第十二次人獸共患病學(xué)術(shù)研討會(huì)暨第六屆第十四次教學(xué)專業(yè)委員會(huì)論文集[C];2012年

2 閆若潛;謝彩華;張志凌;劉梅芬;盛敏;吳志明;;雞基因工程重組復(fù)合抗病毒制劑研究[A];中國畜牧獸醫(yī)學(xué)會(huì)2008年學(xué)術(shù)年會(huì)暨第六屆全國畜牧獸醫(yī)青年科技工作者學(xué)術(shù)研討會(huì)論文集[C];2008年

3 張國剛;王歡;徐綏緒;;抗病毒制劑中黃芩苷在大鼠體內(nèi)的藥代動(dòng)力學(xué)研究[A];藥用植物研究與中藥現(xiàn)代化——第四屆全國藥用植物學(xué)與植物藥學(xué)術(shù)研討會(huì)論文集[C];2004年

4 楊勁;李杰;吳南屏;呂杭軍;張永樂;徐岱;;SMAP與競爭探針聯(lián)合使用檢測(cè)點(diǎn)突變[A];2012年浙江省醫(yī)學(xué)會(huì)肝病、感染病學(xué)學(xué)術(shù)年會(huì)暨浙江省感染科醫(yī)師學(xué)術(shù)年會(huì)論文集[C];2012年

相關(guān)博士學(xué)位論文 前1條

1 王臨旭;植物蛋白MAP30的制備及其體外抗病毒活性的實(shí)驗(yàn)研究[D];中國人民解放軍第四軍醫(yī)大學(xué);2003年

相關(guān)碩士學(xué)位論文 前3條

1 郭圓;殺蟲劑和抗病毒制劑對(duì)蚜蟲翅型分化及發(fā)育和生殖的影響[D];華中農(nóng)業(yè)大學(xué);2016年

2 王靜;中藥抗病毒制劑治療年輕女性宮頸高危型HPV感染的臨床觀察[D];南京中醫(yī)藥大學(xué);2016年

3 張代寶;雞基因工程復(fù)合抗病毒制劑的凍干、安全性及體外抗病毒活性研究[D];河南科技大學(xué);2012年

，

本文編號(hào)：2397059